T. Rowe Price Associates’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $622M | Buy |
10,250,238
+3,370,763
| +49% | +$196M | 0.07% | 219 |
|
|
2025
Q4 | $371M | Sell |
6,879,475
-839,622
| -11% | -$40.4M | 0.04% | 314 |
|
|
2025
Q3 | $348M | Buy |
7,719,097
+445,482
| +6% | +$20.8M | 0.04% | 332 |
|
|
2025
Q2 | $337M | Buy |
7,273,615
+1,484,239
| +26% | +$72.9M | 0.04% | 323 |
|
|
2025
Q1 | $353M | Sell |
5,789,376
-1,738,535
| -23% | -$101M | 0.04% | 319 |
|
|
2024
Q4 | $426M | Sell |
7,527,911
-12,711,872
| -63% | -$710M | 0.05% | 294 |
|
|
2024
Q3 | $1.05B | Buy |
20,239,783
+4,939,412
| +32% | +$232M | 0.12% | 162 |
|
|
2024
Q2 | $635M | Buy |
15,300,371
+2,752,548
| +22% | +$123M | 0.08% | 224 |
|
|
2024
Q1 | $680M | Buy |
12,547,823
+5,461,767
| +77% | +$278M | 0.08% | 221 |
|
|
2023
Q4 | $364M | Buy |
7,086,056
+401,783
| +6% | +$21.1M | 0.05% | 304 |
|
|
2023
Q3 | $388M | Buy |
6,684,273
+554,532
| +9% | +$34M | 0.06% | 279 |
|
|
2023
Q2 | $392M | Sell |
6,129,741
-878,078
| -13% | -$58.9M | 0.05% | 278 |
|
|
2023
Q1 | $486M | Sell |
7,007,819
-389,635
| -5% | -$27.5M | 0.07% | 242 |
|
|
2022
Q4 | $532M | Buy |
7,397,454
+1,311,960
| +22% | +$98.9M | 0.09% | 217 |
|
|
2022
Q3 | $433M | Sell |
6,085,494
-8,501,529
| -58% | -$617M | 0.07% | 245 |
|
|
2022
Q2 | $1.12B | Sell |
14,587,023
-1,216,245
| -8% | -$92.6M | 0.14% | 154 |
|
|
2022
Q1 | $1.15B | Buy |
15,803,268
+12,445,264
| +371% | +$836M | 0.12% | 181 |
|
|
2021
Q4 | $209M | Sell |
3,358,004
-541,195
| -14% | -$31.7M | 0.02% | 544 |
|
|
2021
Q3 | $231M | Buy |
3,899,199
+325,660
| +9% | +$21.4M | 0.02% | 500 |
|
|
2021
Q2 | $239M | Sell |
3,573,539
-55,905
| -2% | -$3.65M | 0.02% | 507 |
|
|
2021
Q1 | $229M | Sell |
3,629,444
-305,655
| -8% | -$19M | 0.02% | 518 |
|
|
2020
Q4 | $244M | Sell |
3,935,099
-2,942,142
| -43% | -$181M | 0.03% | 475 |
|
|
2020
Q3 | $415M | Sell |
6,877,241
-1,766,224
| -20% | -$106M | 0.05% | 332 |
|
|
2020
Q2 | $508M | Sell |
8,643,465
-1,051,375
| -11% | -$62.9M | 0.06% | 294 |
|
|
2020
Q1 | $540M | Sell |
9,694,840
-1,468,911
| -13% | -$89.8M | 0.09% | 244 |
|
|
2019
Q4 | $717M | Sell |
11,163,751
-2,321,008
| -17% | -$133M | 0.09% | 235 |
|
|
2019
Q3 | $684M | Buy |
13,484,759
+735,214
| +6% | +$34.6M | 0.1% | 222 |
|
|
2019
Q2 | $578M | Buy |
12,749,545
+3,816,247
| +43% | +$178M | 0.08% | 261 |
|
|
2019
Q1 | $426M | Buy |
8,933,298
+991,653
| +12% | +$49.4M | 0.06% | 293 |
|
|
2018
Q4 | $413M | Sell |
7,941,645
-3,232,970
| -29% | -$174M | 0.07% | 268 |
|
|
2018
Q3 | $694M | Buy |
11,174,615
+565,258
| +5% | +$33.5M | 0.1% | 211 |
|
|
2018
Q2 | $587M | Sell |
10,609,357
-258,159
| -2% | -$13.9M | 0.09% | 223 |
|
|
2018
Q1 | $687M | Sell |
10,867,516
-1,342,479
| -11% | -$86.4M | 0.11% | 198 |
|
|
2017
Q4 | $748M | Sell |
12,209,995
-708,211
| -5% | -$44.3M | 0.12% | 179 |
|
|
2017
Q3 | $823M | Sell |
12,918,206
-560,835
| -4% | -$32.7M | 0.14% | 166 |
|
|
2017
Q2 | $751M | Sell |
13,479,041
-10,079,650
| -43% | -$548M | 0.14% | 173 |
|
|
2017
Q1 | $1.28B | Sell |
23,558,691
-13,458,040
| -36% | -$738M | 0.24% | 103 |
|
|
2016
Q4 | $2.16B | Sell |
37,016,731
-8,123,043
| -18% | -$444M | 0.43% | 51 |
|
|
2016
Q3 | $2.43B | Sell |
45,139,774
-27,116,075
| -38% | -$1.74B | 0.49% | 41 |
|
|
2016
Q2 | $5.31B | Buy |
72,255,849
+7,001,439
| +11% | +$495M | 1.13% | 10 |
|
|
2016
Q1 | $4.17B | Buy |
65,254,410
+16,444,038
| +34% | +$1.04B | 0.89% | 13 |
|
|
2015
Q4 | $3.36B | Buy |
48,810,372
+6,881,745
| +16% | +$455M | 0.71% | 26 |
|
|
2015
Q3 | $2.48B | Buy |
41,928,627
+8,426,181
| +25% | +$535M | 0.55% | 32 |
|
|
2015
Q2 | $2.23B | Buy |
33,502,446
+19,098,742
| +133% | +$1.26B | 0.46% | 42 |
|
|
2015
Q1 | $929M | Sell |
14,403,704
-794,738
| -5% | -$49.8M | 0.19% | 132 |
|
|
2014
Q4 | $897M | Sell |
15,198,442
-261,710
| -2% | -$14.8M | 0.19% | 134 |
|
|
2014
Q3 | $791M | Sell |
15,460,152
-1,284,302
| -8% | -$64.2M | 0.17% | 147 |
|
|
2014
Q2 | $812M | Sell |
16,744,454
-909,460
| -5% | -$44.8M | 0.18% | 143 |
|
|
2014
Q1 | $917M | Buy |
17,653,914
+2,796,015
| +19% | +$149M | 0.21% | 123 |
|
|
2013
Q4 | $790M | Buy |
14,857,899
+733,510
| +5% | +$37.4M | 0.18% | 141 |
|
|
2013
Q3 | $654M | Buy |
14,124,389
+12,730
| +0.1% | +$559K | 0.16% | 163 |
|
|
2013
Q2 | $631M | Buy |
+14,111,659
| New | +$613M | 0.17% | 154 |
|
Other funds holding BMY
VCM
VPM
T. Rowe Price Associates's BMY Position: Q1 2026 in Review
T. Rowe Price Associates increased its Bristol-Myers Squibb (BMY) stake by 49% in Q1 2026, buying an estimated $196M and bringing the position to 10,250,238 shares worth $622M. The position accounts for 0.07% of the portfolio, ranked #219.
T. Rowe Price Associates first reported a position in BMY in Q2 2013 and has held it in 52 quarters since. The position peaked at $5.31B in Q2 2016. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- T. Rowe Price Associates held 10,250,238 shares of Bristol-Myers Squibb worth $622M as of Q1 2026.
- T. Rowe Price Associates bought 3,370,763 Bristol-Myers Squibb shares in Q1 2026, an estimated $196M.
- Bristol-Myers Squibb made up 0.07% of T. Rowe Price Associates's portfolio in Q1 2026, its #219 holding.
- T. Rowe Price Associates first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 52 quarters since.
- T. Rowe Price Associates's Bristol-Myers Squibb position peaked at $5.31B in Q2 2016.
- 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.